Lifevantage (NASDAQ:LFVN) Updates FY 2026 Earnings Guidance

Lifevantage (NASDAQ:LFVN) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.600-0.600 for the period, compared to the consensus estimate of 0.670. The company issued revenue guidance of $185.0 million-$185.0 million, compared to the consensus revenue estimate of $193.0 million.

Lifevantage Stock Up 9.3%

NASDAQ LFVN opened at $6.00 on Thursday. Lifevantage has a 52 week low of $3.90 and a 52 week high of $15.00. The company has a market capitalization of $76.86 million, a P/E ratio of 10.00 and a beta of 0.52. The stock’s 50-day moving average price is $4.70 and its 200-day moving average price is $5.81.

Lifevantage (NASDAQ:LFVN) last released its earnings results on Wednesday, May 6th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.04). Lifevantage had a return on equity of 29.59% and a net margin of 3.74%.The firm had revenue of $43.72 million during the quarter, compared to analysts’ expectations of $47.77 million. Research analysts anticipate that Lifevantage will post 0.65 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on LFVN. Weiss Ratings lowered Lifevantage from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. Lake Street Capital restated a “buy” rating on shares of Lifevantage in a research report on Thursday, February 5th. Finally, Loop Capital set a $5.00 target price on Lifevantage in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Lifevantage has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Insiders Place Their Bets

In related news, Director Judd Dayton bought 18,097 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average cost of $4.63 per share, with a total value of $83,789.11. Following the completion of the purchase, the director owned 69,859 shares of the company’s stock, valued at approximately $323,447.17. The trade was a 34.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have acquired 38,207 shares of company stock worth $178,585 over the last three months. Company insiders own 21.95% of the company’s stock.

Institutional Investors Weigh In On Lifevantage

Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Lifevantage by 870.2% in the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after buying an additional 4,499 shares in the last quarter. Franklin Resources Inc. purchased a new position in Lifevantage during the 4th quarter valued at approximately $74,000. Jain Global LLC purchased a new position in Lifevantage during the 4th quarter valued at approximately $76,000. Aristides Capital LLC bought a new stake in Lifevantage in the 4th quarter worth approximately $76,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Lifevantage in the 2nd quarter worth approximately $76,000. 35.32% of the stock is owned by institutional investors.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.